Synopsis : Indian pharmaceutical outsourcing companies are back in focus after the US Department of Defense added Chinese biotech giant WuXi AppTec to its list of military-linked entities. Jefferies believes the move could accelerate global supply-chain diversification and create fresh opportunities for Indian CRDMO players, with Sai Life Sciences and Divi’s Laboratories emerging as its preferred picks.
US Action Against WuXi AppTec Puts Indian Pharma In Spotlight
The Indian pharmaceutical sector is attracting renewed investor attention after the US Department of Defense recently expanded its list of companies identified as having links to the Chinese military.
Among the latest additions was Chinese pharmaceutical services giant WuXi AppTec, alongside several major Chinese technology and industrial companies.
According to global brokerage Jefferies, this development could prove beneficial for Indian Contract Research, Development and Manufacturing Organizations (CRDMOs), as global pharmaceutical companies increasingly seek alternative partners outside China.
Jefferies’ Top Picks: Sai Life Sciences And Divi’s Laboratories
Jefferies has identified Sai Life Sciences and Divi’s Laboratories as its preferred beneficiaries of the evolving global pharmaceutical outsourcing landscape.
The brokerage believes both companies possess strong capabilities in small-molecule development and manufacturing while also expanding into high-growth areas such as peptide production.
In addition to these two companies, Jefferies also highlighted Laurus Labs as a potential beneficiary of shifting global supply chains.
However, Sai Life Sciences and Divi’s Laboratories remain the brokerage’s most preferred names due to their established execution track records, customer relationships, and ongoing capacity expansion initiatives.
Why WuXi AppTec’s Inclusion Matters
According to Jefferies, WuXi AppTec’s inclusion on the US Department of Defense’s Section 1260H list could have significant long-term implications.
The designation acts as a trigger within the broader framework of the proposed BIOSECURE Act, a US legislative effort designed to reduce reliance on certain Chinese biotechnology companies for government-funded projects and procurement.
If implemented fully, these restrictions could limit the ability of designated companies to participate in federal contracts and government-supported healthcare initiatives.
Understanding The BIOSECURE Act
The BIOSECURE Act aims to restrict US government agencies and federally funded organizations from procuring biotechnology services or equipment from companies classified as “Biotechnology Companies of Concern.”
According to Jefferies, while regulatory implementation will likely occur gradually, meaningful contracting restrictions could begin taking effect between 2027 and 2028.
As pharmaceutical companies prepare for potential regulatory changes, many may begin diversifying supply chains and outsourcing relationships well before the final deadlines.
Why India Could Benefit
India has steadily strengthened its position as a global pharmaceutical manufacturing and research hub over the past decade.
Several Indian CRDMO companies now offer comprehensive services ranging from drug discovery and clinical development to large-scale commercial manufacturing.
Jefferies estimates that the Indian CRDMO industry generated approximately $3–3.5 billion in revenue during FY26. While this remains smaller than WuXi AppTec’s reported revenue of around $6.3 billion in 2025, the potential market opportunity remains significant.
The brokerage believes companies with expertise in small molecules and peptide manufacturing could capture a meaningful share of future outsourcing demand if global pharmaceutical companies accelerate diversification away from China.
What Investors Should Monitor
While the development appears positive for Indian CRDMO companies, investors should closely monitor:
- Progress of the BIOSECURE Act and related regulations
- Global pharmaceutical outsourcing trends
- New contract wins by Indian CRDMO companies
- Capacity expansion timelines
- Growth in peptide and specialty manufacturing segments
- Changes in US-China trade and regulatory relations
Conclusion
Jefferies believes the evolving regulatory environment in the United States could create a long-term growth opportunity for India's pharmaceutical outsourcing industry. With strong capabilities in research, development, and manufacturing, Sai Life Sciences and Divi’s Laboratories are emerging as key contenders to benefit from potential shifts in global pharmaceutical supply chains.
As regulatory developments continue to unfold, investors will be watching closely to see whether Indian CRDMOs can convert these opportunities into meaningful revenue growth and market share gains.
.jpg)
